Factor VIII - Adverse effects
Research News and Information

Sunday, November 22, 2009

Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses.

21 Jun 2009 The development of neutralizing antibodies (inhibitors) after factor VIII (FVIII) infusions is a serious complication that affects approximately one-quarter of hemophilia A patients who have access to replacement therapy. To investigate the ... Read more...

Therapeutic properties and safety of recombinant factor VIII and factor IX.

30 May 2009 Advances in hemophilia management in the 20th century enabled effective and early treatment of joint and other bleeds typical of this disease, also in a home setting. Prophylaxis became available as the optimal approach to prevent hemophilic ... Read more...

Quantifying the source of infection for HIV-infected hemophiliacs in the U.K. from 1979 to 1984.

29 Apr 2009 There is considerable literature on the risk of HIV infection for individuals suffering from hemophilia A in the United Kingdom (U.K.) during the period 1979-1984 when the sources of Factor VIII clotting factor were contaminated with HIV. Toward the ... Read more...

Latest indexed articles for 'Factor VIII - Adverse effects'

These are the very latest articles for this heading:

• Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. 21 Jun 2009
• Therapeutic properties and safety of recombinant factor VIII and factor IX. 30 May 2009
• Quantifying the source of infection for HIV-infected hemophiliacs in the U.K. from 1979 to 1984. 29 Apr 2009
• The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease. 27 Feb 2009
• Haemophilia patient had variant CJD agent in spleen. 16 Feb 2009
• Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. 30 Dec 2008
• Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience. 30 Oct 2008
• Efficacy and safety of recombinant factor VIII products in patients with hemophilia A. 29 Sep 2008
• Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage. 30 Aug 2008
• Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a computer-aided diary: a Nordic multicentre study. 18 Aug 2008
• Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. 30 Jul 2008
• [Diagnostic image (379). A confused man with tetraparesis and haemophilia] 3 Jul 2008
• An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A. 29 Jun 2008
• Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. 20 May 2008
• Additional antihemophilic factor to be available. 30 Mar 2008
• Advances in the treatment of hemophilia. 28 Feb 2008
• Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study. 26 Feb 2008
• A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. 6 Jan 2008
• Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A. 30 Dec 2007
• Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. 30 Dec 2007

See a longer list of these articles.

Technical information about 'Factor VIII'

Definition: Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.

Chemical name: Blood-coagulation factor VIII, complex

Registry Number: 9001-27-8

Descriptor UI: D005169

Alternative terms: Factor VIII; Thromboplastinogen; Coagulation Factor VIII; Factor VIII, Coagulation; VIII, Coagulation Factor; Antihemophilic Factor; Blood Coagulation Factor VIII; Factor VIII Procoagulant Activity; Factor VIII-Heavy Chain; Factor VIII Heavy Chain; Factor VIIIC; F VIII-C; F VIII C; Humate-P; Humate P; HumateP; Hyatt-C; Hyatt C; HyattC; Hyate-C; Hyate C; HyateC; Monoclate; Factor VIII Coagulant Antigen; Factor VIII Clotting Antigen; Hemofil; Hemofil M; Hemophil; Hemofil HM;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Pharmacological Action: Coagulants;

Tree Number: D12.776.124.125.350; D23.119.350;